One of the most 15 last years and current very efficacious treatments for anti-rejection of the grafts is anti-IL2Receptor (anti-IL2R) .
Targeting the lymphocyte T, these antibodies are able to stop the activation of the lymphocyte T, which is the effector of the rejection phenomenon.
Efficacy of transplantation for kidney grafts is nowadays better and better, but it is still dependent on the graft quality
